A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.
Kulke MH, Ruszniewski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, Brase JC, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC.
Kulke MH, et al. Among authors: riechelmann rp.
Ann Oncol. 2019 Nov 1;30(11):1846. doi: 10.1093/annonc/mdz219.
Ann Oncol. 2019.
PMID: 31407000
Free PMC article.
No abstract available.